IP Library Granted Patent US 7,147,874
Granted Patent B2
US 7,147,874 · App. 10/328,301 · Granted Dec 12, 2006

Pharmaceutical composition for prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,147,874
App. No.
10/328,301
Granted
Dec 12, 2006
Kind
B2
Abstract

A pharmaceutical composition for the prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation is provided. The composition contains purified sumsoo extract and purified ginseng extract containing saponin as the main component, without other herbal essential oil components.

Claims (7)

1. A pharmaceutical composition for the prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation, the pharmaceutical composition comprising an herbal component, wherein the herbal component consists of purified sumsoo extract and purified ginseng extract containing saponin,

wherein the purified sumsoo extract is obtained by using at least one solvent selected from the group consisting of ethylacetate, dichloromethane, and chloroform as an extraction solvent; and

wherein the purified ginseng extract is obtained through solvent fractionation or column chromatography after being extracted using ethanol.

2. The pharmaceutical composition of claim 1 , wherein the purified sumsoo extract is contained in an amount of 0.01–3% by weight and the purified ginseng extract is contained in an amount of 0.01–5% by weight based on the total weight of the pharmaceutical composition.

3. The pharmaceutical composition of claim 1 , further comprising a percutaneous absorption enhancer.

4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in gel form.

5. The pharmaceutical composition of claim 3 , wherein the percutaneous absorption enhancer is selected from the group consisting of Propylene Glycol Monolaurate, N-Methyl-2-Pyrrolidone, Diethylene Glycol Monoethyl Ether, and a mixture of the forgoing substances.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2014
From: CJ HEALTHCARE CORPORATION
To: CHOI, HYUNG KI
Reel/Frame 034152/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2014
From: CJ CHEILJEDANG CORPORATION
To: CJ HEALTHCARE CORPORATION
Reel/Frame 033374/0309 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2008
From: CJ CORPORATION
To: CJ CHEILJEDANG CORPORATION
Reel/Frame 020891/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2002
From: KANG, JIN-AH; HAM, TAE-JIN; KANG, HEE-CHOL; CHO, HI-JAE; KIM, YOUNG-HOON; JEONG, SEONG-HAK
To: CJ CORP.
Reel/Frame 013630/0170 →